Franklin Genomic Beta vs. One Year Return
| HELX Etf | USD 30.44 0.58 1.94% |
For Franklin Genomic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Franklin Genomic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Franklin Genomic Advancements utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Franklin Genomic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Franklin Genomic Advancements over time as well as its relative position and ranking within its peers.
Franklin |
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Franklin Genomic Adv One Year Return vs. Beta Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Franklin Genomic's current stock value. Our valuation model uses many indicators to compare Franklin Genomic value to that of its competitors to determine the firm's financial worth. Franklin Genomic Advancements is rated # 2 ETF in beta as compared to similar ETFs. It is one of the top ETFs in one year return as compared to similar ETFs reporting about 6.67 of One Year Return per Beta. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Franklin Genomic's earnings, one of the primary drivers of an investment's value.Franklin One Year Return vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Franklin Genomic |
| = | 1.14 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
Franklin Genomic |
| = | 7.60 % |
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
Franklin One Year Return Comparison
Franklin Genomic is currently under evaluation in one year return as compared to similar ETFs.
Beta Analysis
Franklin Genomic returns are very sensitive to returns on the market. As the market goes up or down, Franklin Genomic is expected to follow.
Franklin Genomic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Franklin Genomic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Franklin Genomic will eventually generate negative long term returns. The profitability progress is the general direction of Franklin Genomic's change in net profit over the period of time. It can combine multiple indicators of Franklin Genomic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Under normal market conditions, the fund invests at least 80 percent of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. Franklin Genomic is traded on BATS Exchange in the United States.
Franklin Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Franklin Genomic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Franklin Genomic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Franklin Genomic's important profitability drivers and their relationship over time.
Use Franklin Genomic in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Franklin Genomic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Franklin Genomic will appreciate offsetting losses from the drop in the long position's value.Franklin Genomic Pair Trading
Franklin Genomic Advancements Pair Trading Analysis
The ability to find closely correlated positions to Franklin Genomic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Franklin Genomic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Franklin Genomic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Franklin Genomic Advancements to buy it.
The correlation of Franklin Genomic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Franklin Genomic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Franklin Genomic Adv moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Franklin Genomic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Franklin Genomic position
In addition to having Franklin Genomic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
To fully project Franklin Genomic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Franklin Genomic Adv at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Franklin Genomic's income statement, its balance sheet, and the statement of cash flows.